| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 40 | 2023 | 738 | 5.220 |
Why?
|
| Critical Illness | 28 | 2022 | 739 | 3.520 |
Why?
|
| Shock, Septic | 6 | 2024 | 188 | 2.980 |
Why?
|
| Critical Care | 22 | 2023 | 796 | 2.470 |
Why?
|
| Triage | 5 | 2021 | 255 | 1.990 |
Why?
|
| Sepsis | 6 | 2022 | 686 | 1.920 |
Why?
|
| Cancer Care Facilities | 8 | 2022 | 907 | 1.510 |
Why?
|
| Neoplasms | 26 | 2024 | 15927 | 1.420 |
Why?
|
| Thrombelastography | 3 | 2017 | 67 | 1.290 |
Why?
|
| Tracheostomy | 6 | 2017 | 255 | 1.090 |
Why?
|
| Hospital Mortality | 10 | 2022 | 1234 | 1.070 |
Why?
|
| Respiratory Insufficiency | 3 | 2023 | 344 | 1.010 |
Why?
|
| Pandemics | 3 | 2023 | 1610 | 0.910 |
Why?
|
| Hypoxia | 2 | 2020 | 472 | 0.860 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 625 | 0.830 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 700 | 0.820 |
Why?
|
| Health Care Rationing | 2 | 2020 | 80 | 0.810 |
Why?
|
| Patient Discharge | 2 | 2017 | 698 | 0.780 |
Why?
|
| Patient Admission | 4 | 2019 | 231 | 0.740 |
Why?
|
| Length of Stay | 8 | 2017 | 2007 | 0.720 |
Why?
|
| Positive-Pressure Respiration | 2 | 2020 | 123 | 0.710 |
Why?
|
| Prone Position | 1 | 2020 | 59 | 0.710 |
Why?
|
| Terminal Care | 5 | 2022 | 467 | 0.690 |
Why?
|
| Immunocompromised Host | 1 | 2024 | 719 | 0.680 |
Why?
|
| Myasthenia Gravis | 2 | 2023 | 106 | 0.670 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2015 | 334 | 0.670 |
Why?
|
| Analgesia | 1 | 2019 | 97 | 0.630 |
Why?
|
| Patient Positioning | 1 | 2020 | 196 | 0.620 |
Why?
|
| Betacoronavirus | 2 | 2020 | 514 | 0.620 |
Why?
|
| Mexiletine | 1 | 2017 | 5 | 0.610 |
Why?
|
| Respiration, Artificial | 5 | 2017 | 585 | 0.600 |
Why?
|
| Embolism, Air | 1 | 2017 | 35 | 0.590 |
Why?
|
| Delirium | 1 | 2019 | 209 | 0.550 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 115 | 0.540 |
Why?
|
| Thrombophilia | 2 | 2007 | 55 | 0.540 |
Why?
|
| Noninvasive Ventilation | 1 | 2017 | 40 | 0.540 |
Why?
|
| Anesthetics, Local | 1 | 2017 | 178 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 6 | 2020 | 2400 | 0.530 |
Why?
|
| Humans | 84 | 2024 | 270740 | 0.520 |
Why?
|
| Anesthesia | 1 | 2019 | 301 | 0.520 |
Why?
|
| Magnesium Sulfate | 1 | 2015 | 56 | 0.510 |
Why?
|
| Aminocaproic Acid | 1 | 2014 | 17 | 0.490 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2015 | 89 | 0.490 |
Why?
|
| Nutritional Support | 1 | 2015 | 79 | 0.480 |
Why?
|
| Organ Dysfunction Scores | 5 | 2020 | 69 | 0.470 |
Why?
|
| Disaster Planning | 2 | 2005 | 69 | 0.470 |
Why?
|
| Nutritional Requirements | 1 | 2015 | 185 | 0.460 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 1956 | 0.460 |
Why?
|
| Calorimetry, Indirect | 2 | 2015 | 57 | 0.450 |
Why?
|
| Endotoxemia | 1 | 2014 | 72 | 0.450 |
Why?
|
| Middle Aged | 42 | 2022 | 90352 | 0.450 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 220 | 0.440 |
Why?
|
| Disasters | 2 | 2005 | 107 | 0.440 |
Why?
|
| Blood Coagulation | 1 | 2014 | 168 | 0.440 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2022 | 1840 | 0.430 |
Why?
|
| Hemorrhage | 2 | 2014 | 727 | 0.430 |
Why?
|
| Steroids | 1 | 2014 | 372 | 0.420 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 4372 | 0.420 |
Why?
|
| Multiple Organ Failure | 3 | 2012 | 177 | 0.420 |
Why?
|
| Leukemia, Myeloid | 1 | 2017 | 993 | 0.410 |
Why?
|
| Energy Intake | 1 | 2015 | 521 | 0.410 |
Why?
|
| Lung Diseases | 2 | 2014 | 755 | 0.400 |
Why?
|
| Point-of-Care Systems | 2 | 2014 | 212 | 0.390 |
Why?
|
| Pulmonary Embolism | 3 | 2016 | 342 | 0.390 |
Why?
|
| Adult | 34 | 2022 | 82040 | 0.380 |
Why?
|
| Resuscitation Orders | 2 | 2011 | 70 | 0.380 |
Why?
|
| Immunotherapy | 2 | 2021 | 3557 | 0.360 |
Why?
|
| Withholding Treatment | 2 | 2019 | 155 | 0.350 |
Why?
|
| Blood Gas Analysis | 1 | 2010 | 107 | 0.350 |
Why?
|
| Thrombocytopenia | 1 | 2015 | 870 | 0.350 |
Why?
|
| Pain Management | 3 | 2020 | 712 | 0.340 |
Why?
|
| Leukocytosis | 1 | 2010 | 123 | 0.340 |
Why?
|
| Acute Disease | 6 | 2017 | 2493 | 0.330 |
Why?
|
| Retrospective Studies | 22 | 2022 | 39890 | 0.330 |
Why?
|
| Aged | 32 | 2022 | 73333 | 0.330 |
Why?
|
| Heparin | 2 | 2013 | 342 | 0.320 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2022 | 126 | 0.320 |
Why?
|
| Female | 39 | 2022 | 148940 | 0.320 |
Why?
|
| Lung | 2 | 2020 | 3298 | 0.310 |
Why?
|
| Male | 43 | 2022 | 128315 | 0.310 |
Why?
|
| Inpatients | 1 | 2013 | 683 | 0.310 |
Why?
|
| Histamine H2 Antagonists | 1 | 2008 | 58 | 0.310 |
Why?
|
| Vasospasm, Intracranial | 2 | 2004 | 24 | 0.300 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2017 | 7044 | 0.300 |
Why?
|
| Energy Metabolism | 2 | 2015 | 997 | 0.290 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2007 | 34 | 0.290 |
Why?
|
| Cardiac Output | 2 | 2004 | 194 | 0.280 |
Why?
|
| Texas | 6 | 2017 | 6449 | 0.270 |
Why?
|
| Ipratropium | 1 | 2005 | 9 | 0.260 |
Why?
|
| Anisocoria | 1 | 2005 | 7 | 0.260 |
Why?
|
| Xenon | 2 | 2004 | 22 | 0.260 |
Why?
|
| Proton Pump Inhibitors | 1 | 2008 | 271 | 0.260 |
Why?
|
| ROC Curve | 3 | 2021 | 1248 | 0.250 |
Why?
|
| Masks | 1 | 2005 | 59 | 0.250 |
Why?
|
| Aged, 80 and over | 12 | 2018 | 30998 | 0.250 |
Why?
|
| Cholinergic Antagonists | 1 | 2005 | 61 | 0.250 |
Why?
|
| Anticoagulants | 2 | 2013 | 775 | 0.250 |
Why?
|
| Craniotomy | 1 | 2007 | 304 | 0.240 |
Why?
|
| Gastric Mucosa | 1 | 2008 | 660 | 0.240 |
Why?
|
| Cerebrovascular Circulation | 2 | 2004 | 514 | 0.230 |
Why?
|
| Hospitalization | 4 | 2023 | 2167 | 0.230 |
Why?
|
| Medical Errors | 1 | 2006 | 210 | 0.220 |
Why?
|
| Leukemia | 1 | 2012 | 1719 | 0.220 |
Why?
|
| Time Factors | 10 | 2017 | 13006 | 0.220 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 334 | 0.220 |
Why?
|
| Anemia | 1 | 2009 | 728 | 0.220 |
Why?
|
| Death | 4 | 2022 | 130 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2022 | 13414 | 0.210 |
Why?
|
| Trauma Centers | 1 | 2004 | 189 | 0.210 |
Why?
|
| Myositis | 1 | 2023 | 87 | 0.210 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2016 | 347 | 0.210 |
Why?
|
| Young Adult | 9 | 2018 | 22251 | 0.210 |
Why?
|
| Blood Pressure | 3 | 2009 | 1568 | 0.200 |
Why?
|
| Obesity | 1 | 2015 | 2904 | 0.200 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 882 | 0.200 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 761 | 0.200 |
Why?
|
| Comprehensive Health Care | 1 | 2022 | 48 | 0.200 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 379 | 0.200 |
Why?
|
| Incidence | 5 | 2017 | 5824 | 0.200 |
Why?
|
| Professional-Family Relations | 1 | 2022 | 131 | 0.190 |
Why?
|
| Mindfulness | 1 | 2022 | 56 | 0.190 |
Why?
|
| Myocarditis | 1 | 2023 | 181 | 0.190 |
Why?
|
| Benzodiazepines | 2 | 2019 | 167 | 0.190 |
Why?
|
| Decision Trees | 2 | 2019 | 181 | 0.190 |
Why?
|
| Cohort Studies | 5 | 2017 | 9470 | 0.190 |
Why?
|
| Area Under Curve | 3 | 2017 | 729 | 0.190 |
Why?
|
| Life Support Care | 1 | 2021 | 52 | 0.190 |
Why?
|
| Multivariate Analysis | 5 | 2023 | 4328 | 0.190 |
Why?
|
| Hypnotics and Sedatives | 2 | 2019 | 213 | 0.180 |
Why?
|
| Hemoglobins | 2 | 2015 | 482 | 0.180 |
Why?
|
| Decision Making | 3 | 2021 | 1252 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2019 | 78 | 0.170 |
Why?
|
| Midazolam | 1 | 2019 | 72 | 0.170 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 318 | 0.160 |
Why?
|
| Evidence-Based Medicine | 3 | 2019 | 1034 | 0.160 |
Why?
|
| Medical Audit | 2 | 2010 | 195 | 0.160 |
Why?
|
| Conscious Sedation | 1 | 2019 | 102 | 0.160 |
Why?
|
| Logistic Models | 4 | 2020 | 3444 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2022 | 224 | 0.160 |
Why?
|
| Referral and Consultation | 2 | 2016 | 931 | 0.160 |
Why?
|
| Renal Replacement Therapy | 1 | 2020 | 151 | 0.150 |
Why?
|
| Comorbidity | 3 | 2022 | 2394 | 0.150 |
Why?
|
| Risk Factors | 7 | 2017 | 17888 | 0.150 |
Why?
|
| Systems Integration | 1 | 2018 | 68 | 0.150 |
Why?
|
| Biological Products | 1 | 2022 | 319 | 0.150 |
Why?
|
| Echocardiography | 2 | 2021 | 1228 | 0.150 |
Why?
|
| Sodium Chloride | 1 | 2017 | 159 | 0.140 |
Why?
|
| Physicians | 2 | 2016 | 854 | 0.140 |
Why?
|
| Bronchoscopy | 2 | 2017 | 481 | 0.140 |
Why?
|
| Muscle Weakness | 1 | 1997 | 111 | 0.140 |
Why?
|
| Palliative Care | 4 | 2022 | 2178 | 0.140 |
Why?
|
| Organizational Policy | 1 | 2016 | 74 | 0.130 |
Why?
|
| Medical Overuse | 1 | 2016 | 51 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 855 | 0.130 |
Why?
|
| Random Allocation | 1 | 2017 | 741 | 0.130 |
Why?
|
| Intracranial Pressure | 1 | 1997 | 197 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 130 | 0.130 |
Why?
|
| Anesthesia, Intravenous | 1 | 1995 | 39 | 0.130 |
Why?
|
| Rifampin | 2 | 2013 | 218 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 600 | 0.120 |
Why?
|
| Urine | 1 | 1995 | 135 | 0.120 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 1255 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2022 | 914 | 0.120 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 625 | 0.120 |
Why?
|
| Propofol | 1 | 1995 | 77 | 0.120 |
Why?
|
| Algorithms | 2 | 2020 | 3891 | 0.120 |
Why?
|
| Swine, Miniature | 1 | 2014 | 71 | 0.120 |
Why?
|
| Minocycline | 2 | 2013 | 189 | 0.120 |
Why?
|
| Medical Futility | 1 | 2015 | 57 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 681 | 0.120 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 248 | 0.120 |
Why?
|
| Platelet Count | 1 | 2015 | 492 | 0.120 |
Why?
|
| Nutrition Policy | 1 | 2015 | 109 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2007 | 5681 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2017 | 2315 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 250 | 0.110 |
Why?
|
| Advance Directives | 1 | 2015 | 89 | 0.110 |
Why?
|
| Hepatitis, Chronic | 1 | 2013 | 14 | 0.110 |
Why?
|
| Hospitals | 1 | 2017 | 484 | 0.110 |
Why?
|
| Dalteparin | 1 | 2013 | 11 | 0.110 |
Why?
|
| Population Surveillance | 1 | 2017 | 647 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2015 | 2232 | 0.110 |
Why?
|
| Prevalence | 2 | 2013 | 3404 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2018 | 625 | 0.110 |
Why?
|
| Chlorhexidine | 1 | 2013 | 80 | 0.110 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 347 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2017 | 2156 | 0.100 |
Why?
|
| Catheters | 1 | 2013 | 133 | 0.100 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 533 | 0.100 |
Why?
|
| Prognosis | 7 | 2022 | 22505 | 0.100 |
Why?
|
| Italy | 1 | 2012 | 191 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 3844 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2015 | 581 | 0.100 |
Why?
|
| Lipopolysaccharides | 1 | 2014 | 589 | 0.100 |
Why?
|
| Biofilms | 1 | 2013 | 204 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2017 | 2311 | 0.100 |
Why?
|
| Creatinine | 2 | 2011 | 529 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 596 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 1302 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2016 | 382 | 0.100 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2010 | 6 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2011 | 1312 | 0.090 |
Why?
|
| Survival Analysis | 4 | 2020 | 9292 | 0.090 |
Why?
|
| Brain Injuries | 1 | 1997 | 776 | 0.090 |
Why?
|
| United States | 3 | 2023 | 15861 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2017 | 3046 | 0.090 |
Why?
|
| Rats | 4 | 2017 | 6441 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 2057 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2017 | 33737 | 0.090 |
Why?
|
| Hemodynamics | 1 | 2014 | 949 | 0.090 |
Why?
|
| Swine | 1 | 2014 | 1607 | 0.090 |
Why?
|
| Terminally Ill | 1 | 2010 | 97 | 0.090 |
Why?
|
| Patient Selection | 1 | 2017 | 2025 | 0.090 |
Why?
|
| Forecasting | 1 | 2012 | 702 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 4958 | 0.080 |
Why?
|
| Hospital Costs | 1 | 2011 | 244 | 0.080 |
Why?
|
| Patient Transfer | 2 | 2016 | 138 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 3187 | 0.080 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2011 | 214 | 0.080 |
Why?
|
| Neuromuscular Blockade | 2 | 2019 | 15 | 0.080 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 418 | 0.080 |
Why?
|
| Infection Control | 1 | 2011 | 278 | 0.080 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2011 | 622 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2013 | 602 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 4481 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2022 | 2828 | 0.080 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 383 | 0.080 |
Why?
|
| Nutrition Assessment | 1 | 2009 | 176 | 0.070 |
Why?
|
| APACHE | 2 | 2013 | 93 | 0.070 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 161 | 0.070 |
Why?
|
| Catheter-Related Infections | 1 | 2011 | 274 | 0.070 |
Why?
|
| Syndrome | 2 | 2023 | 1407 | 0.070 |
Why?
|
| Vena Cava, Superior | 1 | 2007 | 78 | 0.070 |
Why?
|
| Thrombosis | 1 | 2013 | 743 | 0.070 |
Why?
|
| Pregnancy | 1 | 2020 | 8130 | 0.070 |
Why?
|
| Registries | 1 | 2015 | 2211 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2009 | 477 | 0.070 |
Why?
|
| Antithrombin III | 1 | 2007 | 30 | 0.070 |
Why?
|
| Blood Coagulation Tests | 1 | 2007 | 82 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2012 | 1184 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 884 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 6256 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 1093 | 0.070 |
Why?
|
| Asia, Southeastern | 1 | 2005 | 25 | 0.070 |
Why?
|
| Southeastern United States | 1 | 2005 | 49 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 4960 | 0.060 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 2374 | 0.060 |
Why?
|
| Advisory Committees | 2 | 2016 | 196 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2008 | 486 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 1024 | 0.060 |
Why?
|
| Bacteremia | 1 | 2011 | 721 | 0.060 |
Why?
|
| Administration, Inhalation | 1 | 2005 | 300 | 0.060 |
Why?
|
| Survival Rate | 2 | 2018 | 12541 | 0.060 |
Why?
|
| Communications Media | 1 | 2004 | 5 | 0.060 |
Why?
|
| Organizational Case Studies | 1 | 2004 | 36 | 0.060 |
Why?
|
| Electric Power Supplies | 1 | 2004 | 20 | 0.060 |
Why?
|
| Adolescent | 4 | 2011 | 32767 | 0.060 |
Why?
|
| Plasma Volume | 1 | 2023 | 17 | 0.060 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 166 | 0.060 |
Why?
|
| Antidotes | 1 | 2022 | 27 | 0.050 |
Why?
|
| Software | 1 | 2010 | 1355 | 0.050 |
Why?
|
| Head Injuries, Closed | 2 | 1992 | 40 | 0.050 |
Why?
|
| Animals | 5 | 2017 | 61956 | 0.050 |
Why?
|
| Renal Dialysis | 1 | 2009 | 917 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 7381 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2022 | 78 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2007 | 1309 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 15218 | 0.050 |
Why?
|
| Netherlands | 1 | 2020 | 90 | 0.050 |
Why?
|
| Lactic Acid | 1 | 2022 | 310 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2016 | 1320 | 0.040 |
Why?
|
| Contraindications, Drug | 1 | 2019 | 4 | 0.040 |
Why?
|
| Ecuador | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cause of Death | 1 | 2022 | 789 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 72 | 0.040 |
Why?
|
| Chile | 1 | 2019 | 68 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 100 | 0.040 |
Why?
|
| Dilatation | 1 | 1999 | 87 | 0.040 |
Why?
|
| Canada | 1 | 2020 | 440 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2000 | 295 | 0.040 |
Why?
|
| Posture | 2 | 1997 | 190 | 0.040 |
Why?
|
| Family | 1 | 2022 | 783 | 0.040 |
Why?
|
| Health Occupations | 1 | 2018 | 22 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2018 | 37 | 0.040 |
Why?
|
| Neuromuscular Blocking Agents | 1 | 1997 | 9 | 0.040 |
Why?
|
| Anterior Horn Cells | 1 | 1997 | 4 | 0.040 |
Why?
|
| Staff Development | 1 | 2018 | 62 | 0.040 |
Why?
|
| Motor Neuron Disease | 1 | 1997 | 15 | 0.040 |
Why?
|
| Quadriplegia | 1 | 1997 | 41 | 0.040 |
Why?
|
| Paralysis | 1 | 1997 | 54 | 0.040 |
Why?
|
| Transducers, Pressure | 1 | 1997 | 15 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1106 | 0.040 |
Why?
|
| Equipment Design | 1 | 2000 | 1197 | 0.040 |
Why?
|
| Neuromuscular Diseases | 1 | 1997 | 65 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2023 | 1432 | 0.030 |
Why?
|
| Punctures | 1 | 1997 | 102 | 0.030 |
Why?
|
| Muscular Diseases | 1 | 1997 | 161 | 0.030 |
Why?
|
| Muscular Atrophy | 1 | 1997 | 107 | 0.030 |
Why?
|
| Laryngeal Masks | 1 | 2017 | 78 | 0.030 |
Why?
|
| Oxygenators, Membrane | 1 | 1996 | 11 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 16689 | 0.030 |
Why?
|
| Burns | 1 | 2017 | 130 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2019 | 354 | 0.030 |
Why?
|
| Necrosis | 1 | 1997 | 595 | 0.030 |
Why?
|
| Dronabinol | 1 | 1996 | 41 | 0.030 |
Why?
|
| Polyamines | 1 | 1996 | 80 | 0.030 |
Why?
|
| Brain Edema | 2 | 1996 | 95 | 0.030 |
Why?
|
| Research | 1 | 2018 | 427 | 0.030 |
Why?
|
| Hospitalists | 1 | 2016 | 58 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2019 | 1016 | 0.030 |
Why?
|
| Emulsions | 1 | 1995 | 86 | 0.030 |
Why?
|
| Color | 1 | 1995 | 73 | 0.030 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 1995 | 76 | 0.030 |
Why?
|
| Health Resources | 1 | 2016 | 171 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 1996 | 251 | 0.030 |
Why?
|
| Fentanyl | 1 | 1995 | 153 | 0.030 |
Why?
|
| Enterobacter cloacae | 1 | 2013 | 26 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2022 | 1465 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1997 | 565 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 1996 | 220 | 0.030 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2013 | 32 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2013 | 159 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1996 | 391 | 0.030 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 349 | 0.030 |
Why?
|
| Acinetobacter baumannii | 1 | 2013 | 54 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 1997 | 517 | 0.030 |
Why?
|
| Klebsiella pneumoniae | 1 | 2013 | 101 | 0.030 |
Why?
|
| Spermidine | 1 | 1992 | 9 | 0.030 |
Why?
|
| Culture Media | 1 | 2013 | 344 | 0.030 |
Why?
|
| Putrescine | 1 | 1992 | 18 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 5101 | 0.030 |
Why?
|
| Spermine | 1 | 1992 | 25 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1993 | 99 | 0.030 |
Why?
|
| Acetates | 1 | 1993 | 118 | 0.030 |
Why?
|
| Anxiety | 1 | 2019 | 1240 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2013 | 633 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 252 | 0.020 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 11 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2016 | 699 | 0.020 |
Why?
|
| Pain | 1 | 2019 | 1694 | 0.020 |
Why?
|
| Prodrugs | 1 | 1992 | 226 | 0.020 |
Why?
|
| Pneumonia | 1 | 2016 | 796 | 0.020 |
Why?
|
| Mexico | 1 | 2010 | 275 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2009 | 101 | 0.020 |
Why?
|
| Asthma | 1 | 1997 | 895 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1468 | 0.020 |
Why?
|
| Creatine | 1 | 2009 | 60 | 0.020 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2009 | 139 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2009 | 246 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 984 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 1992 | 623 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5315 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 600 | 0.020 |
Why?
|
| Catheterization, Central Venous | 1 | 2011 | 363 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2011 | 6764 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 5923 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2003 | 7783 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2013 | 1305 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2011 | 1076 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 1571 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2011 | 661 | 0.020 |
Why?
|
| Kidney | 1 | 1995 | 2121 | 0.020 |
Why?
|
| Cross Infection | 1 | 2011 | 550 | 0.020 |
Why?
|
| Imidazoles | 1 | 1992 | 1065 | 0.020 |
Why?
|
| Specific Gravity | 2 | 1996 | 6 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 14012 | 0.010 |
Why?
|
| Hemodilution | 1 | 2003 | 17 | 0.010 |
Why?
|
| Phenylephrine | 1 | 2003 | 53 | 0.010 |
Why?
|
| Dobutamine | 1 | 2003 | 59 | 0.010 |
Why?
|
| Cardiotonic Agents | 1 | 2003 | 156 | 0.010 |
Why?
|
| Brain | 1 | 1992 | 4208 | 0.010 |
Why?
|
| Biomarkers | 1 | 2009 | 5051 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 4761 | 0.010 |
Why?
|
| Injections, Intraventricular | 1 | 1996 | 125 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1996 | 666 | 0.010 |
Why?
|
| Acetic Acid | 1 | 1993 | 33 | 0.010 |
Why?
|
| Factor VIII | 1 | 1993 | 65 | 0.010 |
Why?
|
| Blood Component Transfusion | 1 | 1993 | 87 | 0.010 |
Why?
|
| Eflornithine | 1 | 1992 | 60 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1992 | 22 | 0.010 |
Why?
|
| Lipoxygenase Inhibitors | 1 | 1992 | 25 | 0.010 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 1992 | 39 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 455 | 0.010 |
Why?
|
| Body Water | 1 | 1992 | 124 | 0.010 |
Why?
|
| Coronary Artery Bypass | 1 | 1996 | 530 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 9039 | 0.010 |
Why?
|
| Plasma | 1 | 1993 | 146 | 0.010 |
Why?
|
| Fibrinogen | 1 | 1993 | 212 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 1993 | 130 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1992 | 177 | 0.010 |
Why?
|
| Motor Activity | 1 | 1992 | 699 | 0.000 |
Why?
|